Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 0.35 |
| ▸ | TSHR | P16473 | 8/20 | 0.35 |
| ▸ | USP2 | O75604 | 8/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 6/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30553148 | 1.00 | CYP3A4 (0.35) | CYP3A4TSHRUSP2CYP2D6CYP1A2 | |
| SCHEMBL25325093 | 0.93 | MGLL (0.35) | CYP3A4USP2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL30553167 | 0.93 | MGLL (0.35) | CYP3A4USP2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL30553289 | 0.87 | CYP3A4 (0.35) | CYP3A4TSHRUSP2CYP2D6CYP1A2 | |
| SCHEMBL25325523 | 0.87 | CYP3A4 (0.35) | CYP3A4TSHRUSP2CYP2D6CYP1A2 | |
| SCHEMBL25324331 | 0.86 | MGLL (0.37) | CYP3A4TSHRUSP2CYP2D6CYP1A2 | |
| SCHEMBL25325915 | 0.85 | MGLL (0.43) | MGLL | |
| SCHEMBL30553315 | 0.85 | MGLL (0.43) | MGLL | |
| SCHEMBL30012082 | 0.81 | MGLL (0.54) | CYP3A4TSHRUSP2CYP2D6CYP1A2 | |
| SCHEMBL27246221 | 0.81 | MGLL (0.54) | CYP3A4TSHRUSP2CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | CYP3A4 3/4885TSHR 630/4885USP2 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.